Online inquiry

IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11524MR)

This product GTTS-WQ11524MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FGFR3 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000142.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2261
UniProt ID P22607
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11524MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ306MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 19D12
GTTS-WQ4848MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ12639MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ3052MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ13648MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ120MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ9390MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ14687MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SCT-400
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW